Beta Blockers and Gout Risk
Beta blockers as a class increase the risk of gout, with metoprolol being the most problematic, while calcium channel blockers and losartan are preferred alternatives in patients with gout or at risk for gout.
Evidence from Guidelines
The most recent and authoritative gout management guidelines consistently recommend avoiding beta blockers in patients with gout when feasible. The 2017 EULAR guidelines 1 and 2006 EULAR recommendations 2 specifically state that when gout occurs in patients on antihypertensive therapy, clinicians should "consider losartan or calcium channel blockers" for hypertension management. This recommendation reflects the understanding that certain antihypertensives have differential effects on uric acid metabolism.
The 2020 ACR guideline 3 conditionally recommends "choosing losartan preferentially as an antihypertensive agent when feasible" for patients with gout, regardless of disease activity. This guidance implicitly suggests moving away from agents that raise uric acid, including beta blockers.
Research Evidence on Specific Beta Blockers
Most Likely to Cause Gout: Metoprolol
Metoprolol stands out as the beta blocker with the strongest evidence for increasing gout risk. A 2017 randomized controlled trial in African Americans with chronic kidney disease 4 demonstrated that metoprolol:
- Increased serum uric acid by 0.3 mg/dL after 12 months
- Showed significantly higher uric acid levels compared to ramipril (difference of 0.40 mg/dL, p=0.009)
- Increased odds of gout-related medication use (OR 1.62,95% CI 1.03-2.54, p=0.04)
- Nearly quadrupled the risk of gout-related hospitalization compared to ramipril (HR 3.87, though not statistically significant)
Beta Blockers as a Class
A large UK population-based case-control study 5 involving 24,768 incident gout cases found that beta blockers as a class significantly increase gout risk with a multivariate relative risk of 1.48 (95% CI 1.40-1.57) among hypertensive patients. This represents nearly a 50% increased risk compared to non-use.
A 2016 cross-sectional study 6 confirmed that patients treated with beta blockers had:
- Significantly higher serum uric acid levels than those not taking these drugs
- Reduced glomerular filtration rate negatively correlated with uric acid levels
- Gender differences in effects, with variations between men and women
Multiple regression analysis in this study indicated that beta blockers significantly contributed to hyperuricemia in patients on antihypertensive medication 6.
Mechanism
Beta blockers increase uric acid through multiple mechanisms:
- Reduction in glomerular filtration rate 6
- Decreased renal uric acid clearance
- Potential effects on uric acid reabsorption in renal tubules
Least Likely to Cause Gout: Preferred Alternatives
Losartan (ARB)
Losartan is the preferred alternative with uricosuric properties that actually lower uric acid levels. The UK study 5 showed losartan reduced gout risk (RR 0.81,95% CI 0.70-0.94), with longer duration of use providing greater protection (RR 0.71 for ≥2 years, p<0.05 for trend). However, losartan typically lowers uric acid by only ~50 µmol/L 7, which is insufficient as monotherapy for urate-lowering treatment but beneficial when antihypertensive therapy is needed.
Calcium Channel Blockers
Calcium channel blockers showed protective effects with RR 0.87 (95% CI 0.82-0.93) 5, with increasing benefit over time (RR 0.75 for ≥2 years). The 2016 study 6 confirmed that calcium channel blockers did not increase serum uric acid levels.
Clinical Algorithm
For patients with gout or hyperuricemia requiring antihypertensive therapy:
- Avoid beta blockers entirely - particularly metoprolol
- First-line alternatives:
- Losartan (dual benefit: blood pressure control + modest uric acid lowering)
- Calcium channel blockers (neutral to beneficial effect on uric acid)
- If beta blocker is absolutely necessary (e.g., post-MI, heart failure with reduced ejection fraction):
- Use cardioselective agents (bisoprolol, metoprolol succinate) at lowest effective dose
- Ensure aggressive urate-lowering therapy is optimized
- Monitor uric acid levels closely
- Consider switching to carvedilol (combined alpha/beta blocker) which may have less impact
For patients currently on beta blockers who develop gout:
- Switch to losartan or calcium channel blocker when clinically feasible
- Do not abruptly discontinue beta blockers (taper appropriately)
- Initiate or optimize urate-lowering therapy concurrently
Important Caveats
The 2018 ACC/AHA hypertension guidelines 8 note that beta blockers are "not recommended as first-line agents unless the patient has IHD or HF." This aligns with gout management recommendations, as beta blockers should be reserved for specific cardiac indications where their benefits clearly outweigh the increased gout risk.
Recent FAERS database analyses 9, 10, 11 have identified additional signals for various antihypertensive agents, though these real-world pharmacovigilance data should be interpreted cautiously given potential confounding and reporting biases.
The evidence consistently demonstrates that among beta blockers, metoprolol poses the highest gout risk, while losartan and calcium channel blockers represent the safest alternatives for blood pressure management in patients with or at risk for gout.